Hospital Infection Therapeutics Market

Hospital Infection Therapeutics Market (Therapeutics: Anti-bacterial Drugs, Anti-fungal Drugs, Anti-viral Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2031

Hospital Infection Therapeutics Market Outlook 2031

  • The global industry was valued at US$ 11.3 Bn in 2022
  • It is estimated to grow at a CAGR of 2.6% from 2023 to 2031 and reach US$ 14.4 Bn by the end of 2031

Analyst Viewpoint

Rise in antibiotic resistance of bacteria is projected to spur innovation and growth in the global hospital infection therapeutics market. Advancements in diagnostics and drug delivery methods are also anticipated to boost market statistics. Rise in geriatric population is another factor driving the demand for hospital infection therapeutics, since this group is more prone to hospital-acquired infections due to weakened immune system.

Emerging economies present high growth potential to drug manufacturers, with individuals in such countries seeking improved healthcare services owing to the rise in general income levels. Investments in R&D in non-antibiotic treatment options and partnerships for co-development and commercialization of anti-infective agents are likely to further bolster the hospital infection therapeutics market size.

Hospital Infection Therapeutics Market

Market Introduction

Hospital-acquired infections are a common occurrence in the healthcare sector. In low and medium income countries, the presence of unsanitary environments in and around hospitals is a major contributory factor to hospital-acquired infections.

Faulty sterilization procedures and lack of medical facility infection control solutions in these settings also result in an increase in the occurrence of hospital-acquired diseases. Rise in infections caused by resistant bacteria is augmenting the global hospital therapeutics market development.

Companies operating in the global landscape are investing in research and development activities to produce new antibiotics. However, growth in treatment resistance, requirement of large investments due to high attrition rates in clinical trials, and dearth of reimbursement policies are resulting in a restricted pipeline of medications. This is likely to hamper the hospital infection therapeutics market value to a certain extent.

Rise in Antibiotic Resistance of Bacteria Spurring Innovation in Hospital Infection Therapeutics Industry

Over time, microorganisms such as fungi and bacteria develop resistance to drugs that are designed to eliminate them. Thus, they continue to thrive, causing infections among the population. Such resistant infections can often be difficult to treat.

Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly five million deaths in 2019. More than 2.8 million antimicrobial-resistant infections are reported each year in the U.S.

People at any stage of life can be affected by antibiotic resistance. It has the potential to derail industries such as healthcare and agriculture industries. Thus, antibiotic resistance is one of the key public health issues across the world.

Growth in initiatives such as the WHO's Global Action Plan on Antimicrobial Resistance and related programs is likely to augment the demand for anti-bacterial medications during the forecast period. This, in turn, is expected to result in an increase in awareness about hospital infectious disease treatments.

Advancements in Diagnostics and Drug Delivery Methods to Aid Hospital Infection Therapeutics Market Growth

Technological developments in diagnostics, drug delivery, and therapy monitoring are bolstering the sales of healthcare facility infection control drugs. Development of rapid diagnostic tests and point-of-care devices is assisting healthcare personnel in swiftly diagnosing and treating hospital-acquired infections. This is resulting in better patient outcomes and lower risk of infection transmission.

Telemedicine and digital health platforms also increase patient access to healthcare services and allow for remote monitoring of patients with hospital-acquired infections. Furthermore, development of innovative drug delivery technologies, such as nanoparticles and liposomes, enhances treatment efficacy and minimizes toxicity, thereby increasing the effectiveness of hospital infection therapy.

Regional Outlook

As per the global hospital infection therapeutics industry analysis, Europe accounted for significant share of the global industry in 2022. High incidence of hospital-acquired infections, rise in number of surgeries and the resultant hospitalizations, increase in the elderly population, and growth in spending on advanced healthcare are driving the region’s hospital infection therapeutics market share.

North America is another region that is recording significant hospital infection therapeutics market expansion. Presence of highly developed health care infrastructure and larger reimbursement coverage are propelling the market dynamics of the region.

Future analysis of hospital infection therapeutics reveals that the high growth rate of the pharmaceutical industry in India and China is expected to sustain the market trajectory in Asia Pacific. Companies are increasingly investing in China for the development of novel treatment approaches for hospital-acquired infections. These key trends in Asia Pacific are expected to hold strong through 2031.

Analysis of Key Players

The hospital infection therapeutics market report scope includes an analysis of key players operating in the global market. Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company are the prominent companies in the global landscape.

Leading companies such as Merck & Co., Inc. and Pfizer, Inc. are engaged in the manufacture of anti-bacterial drugs. These companies are also investing substantially in research and development activities to overcome drug resistance.

The research report on hospital infection therapeutics market summarizes the prominent players in terms of parameters such as company overview, portfolio, recent developments, business segments, growth strategies, and financial overview.

Key Developments

  • In June, 2023, Pfizer released data from late-stage studies comparing an experimental combination of the antibiotics aztreonam-avibactam (ATM-AVI) and metronidazole, as well as a combination of two older antibiotics - meropenem and colistin - to treat complicated intra-abdominal infections and varieties of hospital-acquired pneumonia
  • In 2021, Sanofi stated that it had met the primary objective of its MELODY Phase III study of nirsevimab in lower respiratory tract infections (LRTI) caused by RSV in healthy late preterm and term newborns. This makes the drug a novel potential treatment for RSV in over two decades.

Hospital Infection Therapeutics Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 11.3 Bn
Market Forecast Value in 2031 US$ 14.4 Bn
Growth Rate (CAGR) 2.6%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2023
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Market Segmentation
  • Therapeutics
    • Anti-bacterial Drugs
    • Anti-fungal Drugs
    • Anti-viral Drugs
    • Others
  • Infection
    • Hospital Acquired Pneumonia
    • Urinary Tract Infections
    • Gastrointestinal Disorders
    • Bloodstream Infections
    • Surgical Site Infections
    • Other Hospital Infections
Companies Profiled
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bayer AG
  • Allergan plc
  • Sanofi S.A.
  • Gilead Sciences, Inc.
  • Basilea Pharmaceutica Ltd.
  • Bristol-Myers Squibb Company
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the global hospital infection therapeutics market in 2022?

It was valued at US$ 11.3 Bn in 2022

How is the hospital infection therapeutics business expected to grow by 2031?

It is likely to grow at a CAGR of 2.6% from 2023 to 2031

What are the key factors driving the demand for hospital infection therapeutics?

Rise in antibiotic resistance of bacteria spurring innovation in hospital infection therapeutics, and advancements in diagnostics and drug delivery methods

Which therapeutics segment holds the largest share in the hospital infection therapeutics industry?

The anti-bacterial drugs segment commands a bulk of the share

Which was the major region in the global hospital infection therapeutics landscape in 2022?

Europe was the leading region in 2022

Who are the key hospital infection therapeutics providers?

Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Allergan plc, Sanofi S.A., Basilea Pharmaceutica Ltd., and Bristol-Myers Squibb Company.

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Hospital Infection Therapeutics Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Hospital Infection Therapeutics Market Analysis and Forecast, 2023-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Disease Prevalence & Incidence Rate Globally With Key Countries

        5.3. COVID-19 Pandemic Impact on Industry

    6. Hospital Infection Therapeutics Market Analysis and Forecast, by Therapeutics

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Therapeutics, 2017–2031

            6.3.1. Anti-bacterial Drugs

            6.3.2. Anti-fungal Drugs

            6.3.3. Anti-viral Drugs

            6.3.4. Others

        6.4. Market Attractiveness, by Therapeutics

    7. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Infection

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Infection, 2017–2031

            7.3.1. Hospital Acquired Pneumonia

            7.3.2. Urinary Tract Infections

            7.3.3. Gastrointestinal Disorders

            7.3.4. Bloodstream Infections

            7.3.5. Surgical Site Infections

            7.3.6. Other Hospital Infections

        7.4. Market Attractiveness, by Infection

    8. Global Hospital Infection Therapeutics Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2017–2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Hospital Infection Therapeutics Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Therapeutics, 2023–2031

            9.2.1. Anti-bacterial Drugs

            9.2.2. Anti-fungal Drugs

            9.2.3. Anti-viral Drugs

            9.2.4. Others

        9.3. Market Value Forecast, by Infection, 2023–2031

            9.3.1. Hospital Acquired Pneumonia

            9.3.2. Urinary Tract Infections

            9.3.3. Gastrointestinal Disorders

            9.3.4. Bloodstream Infections

            9.3.5. Surgical Site Infections

            9.3.6. Other Hospital Infections

        9.4. Market Value Forecast, by Country, 2023–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Therapeutics

            9.5.2. By Infection

            9.5.3. By Country

    10. Europe Hospital Infection Therapeutics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Therapeutics, 2023–2031

            10.2.1. Anti-bacterial Drugs

            10.2.2. Anti-fungal Drugs

            10.2.3. Anti-viral Drugs

            10.2.4. Others

        10.3. Market Value Forecast, by Infection, 2023–2031

            10.3.1. Hospital Acquired Pneumonia

            10.3.2. Urinary Tract Infections

            10.3.3. Gastrointestinal Disorders

            10.3.4. Bloodstream Infections

            10.3.5. Surgical Site Infections

            10.3.6. Other Hospital Infections

        10.4. Market Value Forecast, by Country/Sub-region, 2023–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Therapeutics

            10.5.2. By Infection

            10.5.3. By Country/Sub-region

    11. Asia Pacific Hospital Infection Therapeutics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Therapeutics, 2023–2031

            11.2.1. Anti-bacterial Drugs

            11.2.2. Anti-fungal Drugs

            11.2.3. Anti-viral Drugs

            11.2.4. Others

        11.3. Market Value Forecast, by Infection, 2023–2031

            11.3.1. Hospital Acquired Pneumonia

            11.3.2. Urinary Tract Infections

            11.3.3. Gastrointestinal Disorders

            11.3.4. Bloodstream Infections

            11.3.5. Surgical Site Infections

            11.3.6. Other Hospital Infections

        11.4. Market Value Forecast, by Country/Sub-region, 2023–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Therapeutics

            11.5.2. By Infection

            11.5.3. By Country/Sub-region

    12. Latin America Hospital Infection Therapeutics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Therapeutics, 2023–2031

            12.2.1. Anti-bacterial Drugs

            12.2.2. Anti-fungal Drugs

            12.2.3. Anti-viral Drugs

            12.2.4. Others

        12.3. Market Value Forecast, by Infection, 2023–2031

            12.3.1. Hospital Acquired Pneumonia

            12.3.2. Urinary Tract Infections

            12.3.3. Gastrointestinal Disorders

            12.3.4. Bloodstream Infections

            12.3.5. Surgical Site Infections

            12.3.6. Other Hospital Infections

        12.4. Market Value Forecast, by Country/Sub-region, 2023–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Therapeutics

            12.5.2. By Infection

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Hospital Infection Therapeutics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Therapeutics, 2023–2031

            13.2.1. Anti-bacterial Drugs

            13.2.2. Anti-fungal Drugs

            13.2.3. Anti-viral Drugs

            13.2.4. Others

        13.3. Market Value Forecast, by Infection, 2023–2031

            13.3.1. Hospital Acquired Pneumonia

            13.3.2. Urinary Tract Infections

            13.3.3. Gastrointestinal Disorders

            13.3.4. Bloodstream Infections

            13.3.5. Surgical Site Infections

            13.3.6. Other Hospital Infections

        13.4. Market Value Forecast, by Country/Sub-region, 2023–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Therapeutics

            13.5.2. By Infection

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Merck & Co., Inc.

                14.3.1.1. Company Revenue

                14.3.1.2. Business Overview

                14.3.1.3. Product Segments

                14.3.1.4. Geographic Footprint

                14.3.1.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.1.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.2. Pfizer, Inc.

                14.3.2.1. Company Revenue

                14.3.2.2. Business Overview

                14.3.2.3. Product Segments

                14.3.2.4. Geographic Footprint

                14.3.2.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.2.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.3. GlaxoSmithKline plc

                14.3.3.1. Company Revenue

                14.3.3.2. Business Overview

                14.3.3.3. Product Segments

                14.3.3.4. Geographic Footprint

                14.3.3.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.3.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.4. AstraZeneca

                14.3.4.1. Company Revenue

                14.3.4.2. Business Overview

                14.3.4.3. Product Segments

                14.3.4.4. Geographic Footprint

                14.3.4.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.4.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.5. Johnson & Johnson Services, Inc.

                14.3.5.1. Company Revenue

                14.3.5.2. Business Overview

                14.3.5.3. Product Segments

                14.3.5.4. Geographic Footprint

                14.3.5.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.5.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.6. F. Hoffmann-La Roche Ltd.

                14.3.6.1. Company Revenue

                14.3.6.2. Business Overview

                14.3.6.3. Product Segments

                14.3.6.4. Geographic Footprint

                14.3.6.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.6.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.7. Bayer AG

                14.3.7.1. Company Revenue

                14.3.7.2. Business Overview

                14.3.7.3. Product Segments

                14.3.7.4. Geographic Footprint

                14.3.7.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.7.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.8. Allergan plc.

                14.3.8.1. Company Revenue

                14.3.8.2. Business Overview

                14.3.8.3. Product Segments

                14.3.8.4. Geographic Footprint

                14.3.8.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.8.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.9. Sanofi S.A.

                14.3.9.1. Company Revenue

                14.3.9.2. Business Overview

                14.3.9.3. Product Segments

                14.3.9.4. Geographic Footprint

                14.3.9.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.9.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.10. Gilead Sciences, Inc.

                14.3.10.1. Company Revenue

                14.3.10.2. Business Overview

                14.3.10.3. Product Segments

                14.3.10.4. Geographic Footprint

                14.3.10.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.10.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.11. Basilea Pharmaceutica Ltd.

                14.3.11.1. Company Revenue

                14.3.11.2. Business Overview

                14.3.11.3. Product Segments

                14.3.11.4. Geographic Footprint

                14.3.11.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.11.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

            14.3.12. Bristol-Myers Squibb Company

                14.3.12.1. Company Revenue

                14.3.12.2. Business Overview

                14.3.12.3. Product Segments

                14.3.12.4. Geographic Footprint

                14.3.12.5. Production Capacity/Plant Details, etc. (*As Applicable)

                14.3.12.6. Strategic Partnership, Capacity Expansion, New Product Innovation, etc.

    List of Tables

    Table 1: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2031

    Table 2: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2017–2031

    Table 3: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 4: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 5: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2031

    Table 6: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2017–2031

    Table 7: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 8: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2031

    Table 9: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection 2017–2031

    Table 10: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 11: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2031

    Table 12: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection, 2017–2031

    Table 13: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2031

    Table 15: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection 2017–2031

    Table 16: Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Therapeutics, 2017–2031

    Table 18: Middle East & Africa Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, by Infection 2017–2031

    List of Figures

    Figure 1: Global Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 2: Global Hospital Infection Therapeutics Market Value Share, by Therapeutics, 2022

    Figure 3: Global Hospital Infection Therapeutics Market Value Share, by Infection, 2022

    Figure 4: Global Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 5: Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023–2031

    Figure 6: Global Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031

    Figure 7: Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023–2031

    Figure 8: Global Hospital Infection Therapeutics Market Value Share Analysis, by Region, 2022 and 2031

    Figure 9: Global Hospital Infection Therapeutics Market Attractiveness Analysis, by Region, 2023–2031

    Figure 10: North America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 11: North America Hospital Infection Therapeutics Market Value Share Analysis, by Country, 2022 and 2031

    Figure 12: North America Hospital Infection Therapeutics Market Attractiveness Analysis, by Country, 2023–2031

    Figure 13: North America Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 14: North America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023–2031

    Figure 15: North America Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031

    Figure 16: North America Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023–2031

    Figure 17: Europe Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 18: Europe Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 19: Europe Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 20: Europe Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 21: Europe America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023–2031

    Figure 22: Europe Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031

    Figure 23: Europe Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023–2031

    Figure 24: Asia Pacific Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 25: Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 26: Asia Pacific Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 27: Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 28: Asia Pacific America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023–2031

    Figure 29: Asia Pacific Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031

    Figure 30: Asia Pacific Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023–2031

    Figure 31: Latin America Hospital Infection Therapeutics Market Value (US$ Mn) Forecast, 2017–2031

    Figure 32: Latin America Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33: Latin America Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 34: Latin America Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2022 and 2031

    Figure 35: Latin America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023–2031

    Figure 36: Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 37: Middle East & Africa Hospital Infection Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 38: Middle East & Africa America Hospital Infection Therapeutics Market Value Share Analysis, by Therapeutics, 2023–2031

    Figure 39: Middle East & Africa America Hospital Infection Therapeutics Market Attractiveness Analysis, by Therapeutics, 2023–2031

    Figure 40: Middle East & Africa Hospital Infection Therapeutics Market Value Share Analysis, by Infection, 2022 and 2031

    Figure 41: Middle East & Africa Hospital Infection Therapeutics Market Attractiveness Analysis, by Infection 2023–2031

    Figure 42: Global Hospital Infection Therapeutics Market Share Analysis, by Company (2022)

Copyright © Transparency Market Research, Inc. All Rights reserved